Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Letter Oncology

Second versus first wave of COVID-19 in patients with MPN

Tiziano Barbui et al.

LEUKEMIA (2022)

Article Oncology

Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients

Cinzia Borgogna et al.

Summary: Understanding the immune response to SARS-CoV-2 infection in hematologic malignancy patients is crucial. This study found that therapy-naive patients had a stronger antibody response compared to patients receiving anti-cancer treatment.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Letter Oncology

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study

Martin Schoenlein et al.

CANCER CELL (2022)

Add to Collection

Letter Medicine, General & Internal

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

Gili Regev-Yochay et al.

Summary: Health care workers in Israel received a fourth dose of mRNA vaccine during the prevalence of the omicron variant. The fourth dose boosted antibody levels but did not surpass the maximum observed after the third dose. The vaccine demonstrated an efficacy of 31 to 43% against symptomatic disease.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Meeting Abstract Hematology

Antibody and T -Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients

Joan How et al.

BLOOD (2021)

Add to Collection

Meeting Abstract Hematology

Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?

Giovanni Caocci et al.

BLOOD (2021)

Add to Collection

Meeting Abstract Hematology

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis

Inna Y. Gong et al.

BLOOD (2021)

Add to Collection

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Infectious Diseases

An easy-to-use nomogram for predicting in-hospital mortality risk in COVID-19: a retrospective cohort study in a university hospital

Hazal Cansu Acar et al.

Summary: This study developed a nomogram for clinicians to estimate the risk of in-hospital mortality in COVID-19 patients, which includes factors like age, comorbidities, dyspnea, oxygen saturation, and C-reactive protein. The prediction ability of this nomogram was excellent, which may help reduce mortality in COVID-19 patients through early diagnosis and intervention.

BMC INFECTIOUS DISEASES (2021)

Add to Collection

Letter Oncology

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience

Daniele Cattaneo et al.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Immunology

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors

Daniele Cattaneo et al.

Summary: BCR-ABL1-negative myeloproliferative neoplasms have a reduced life expectancy mainly due to an increased risk of thrombo-hemorrhagic events, fibrotic progression/leukemic evolution, and infectious complications. JAK2V617F is the main driver mutation in these conditions, and JAK inhibitors, while improving symptoms and quality of life for MPN patients, may also lead to adverse events related to immune suppression or deficiency.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Letter Oncology

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Fulvia Pimpinelli et al.

Summary: Among 42 Philadelphia negative myeloproliferative neoplasm patients receiving systemic active treatment, those with myelofibrosis showed significantly lower response to the anti-SARS-CoV-2 BNT162b2 vaccine compared to patients with essential thrombocythemia and polycythemia vera in terms of IgG titers and seroprotection rates. The ongoing treatment with Ruxolitinib in some patients may be associated with reduced vaccine immunogenicity, but further large prospective studies are needed to confirm this finding.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Chemistry, Medicinal

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

Milo Gatti et al.

Summary: There is a paradigm shift in drug development and clinical practice to combat COVID-19, with a focus on testing various pharmacological approaches like JAK inhibitors. These inhibitors possess key characteristics for successful repurposing, including convenient oral administration, favorable pharmacokinetic profiles, and dual anti-inflammatory and anti-viral effects. Efforts are also being made to address safety issues and expand usage in different patient populations.

PHARMACEUTICALS (2021)

Add to Collection

Article Hematology

Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis

Qingsong Luo et al.

Summary: The study found that there was no significant difference in infection risk between ruxolitinib-treated MPN patients and non-ruxolitinib group in the early stage, but the infection risk was significantly lower in the extension phase. However, ruxolitinib increased the risk of herpes zoster infection.

HEMATOLOGY (2021)

Add to Collection

Article Oncology